Pulmonary sclerosing pneumocytoma masquerading adenocarcinoma with co-existing BRAF V600E and PTEN mutation

Dantis, Klein; Gupta, Ashish Kumar; Kashyap, Nitin; Kashyap, Yashwant; Ranganath, T G; Pati, Sanghamitra; Kumar, Mayank; Thakur, Shiva; Ravina, Mudalsha

doi:10.1016/j.ctarc.2021.100429

Cited by 8 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case indicated that pulmonary sclerosing pneumocytoma was not self-limiting despite its benign nature. Some pulmonary sclerosing pneumocytoma cases have been reported with multiple lung involvement [ 39 ], lymph node metastasis [ 8 , 11 , 16 ], and distant metastasis [ 40 ]. Those elucidated the potential malignant nature of pulmonary sclerosing pneumocytoma.…”

Section: Discussionmentioning

confidence: 99%

“…Those elucidated the potential malignant nature of pulmonary sclerosing pneumocytoma. There were theories that lymph node metastasis of pulmonary sclerosing pneumocytoma was mediated through air space pattern [ 11 ]. Dantis and colleagues [ 11 ] reported that PET scan could help guide lymph node dissection, since the cases with SUV max uptake of more than 2.5 mostly had positive mediastinal lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…There were theories that lymph node metastasis of pulmonary sclerosing pneumocytoma was mediated through air space pattern [ 11 ]. Dantis and colleagues [ 11 ] reported that PET scan could help guide lymph node dissection, since the cases with SUV max uptake of more than 2.5 mostly had positive mediastinal lymph node metastasis. Wei and colleagues [ 4 ] reported a pulmonary sclerosing pneumocytoma case with local recurrence 10 years after initial wedge resection.…”

Section: Discussionmentioning

confidence: 99%

“…The molecular alterations in the sclerosing pneumocytoma were one of the study focuses and showed diagnostic value. AKT1 mutation was the most commonly reported gene mutation and was speculated to be the genetic hallmark of sclerosing pneumocytoma [ 11 , 41 , 42 ]. AKT1 mutation might induce cells proliferation and morphology changing, but would not induce progress to malignancy [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

“…According to the WHO categorization of lung and pleural tumors (2018, ICD-11 for Mortality and Morbidity Statistics), pulmonary sclerosing pneumocytoma was categorized as benign, fibromatous neoplasms [ 6 ]. Nevertheless, there have been several reports on the possible malignant characteristics with lymph node metastasis [ 7 – 11 ] or local recurrence [ 12 ]. Although the prognosis of pulmonary sclerosing pneumocytoma seems not to be affected by these malignant potentials, there are other factors which may be related to the prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Zheng

Zhou

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Pulmonary sclerosing pneumocytoma is a kind of rare benign pulmonary tumor with potential malignancy. The clinical features, risk factors for prognosis, and optimal treatment have not been identified yet. This study aimed to investigate the clinical features and prognosis of pulmonary sclerosing pneumocytoma. Methods We retrospectively performed a review of pulmonary sclerosing pneumocytoma patients in West China Hospital from 2009 to 2019. The basic characteristics, treatment regimens, operation detail, postoperative variables, and follow-up time were recorded for each case. Differences in features between patients undergoing lobectomy and segmentectomy were compared. We also performed a case review and summarized reported clinical features in former studies. Results Altogether 61 pulmonary sclerosing pneumocytoma patients were retrospectively reviewed. Fifty-six patients were female and 5 were male. The patients’ median age was 51 (23-73). Seven (11.48%) patients had smoking history. Twenty tumors were located in the right lung [upper lobe (n = 7), middle (n = 2), and lower (n = 11)] and 41 in the left [upper (n = 12) and lower (n = 29)]. The median tumor size was 2 (0.9-7) cm. Thirty-six (59.02%) patients underwent sublobectomy (segmentectomy or wedge resection) whereas 25 (40.98%) underwent lobectomy. All patients recovered uneventfully, and no perioperative mortality was identified. Sublobectomy showed a trend towards reduced chest tube duration and shorter postoperative hospital stays compared with lobectomy. Conclusions The findings showed good prognosis of pulmonary sclerosing pneumocytoma and proved its benign characteristics. Sublobectomy showed advanced efficacy regarding chest tube duration and postoperative hospital stay compared with lobectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Zheng

Zhou

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

Pulmonary Sclerosing Pneumocytoma

Zhang

2023

Diagnostic Imaging of Lung Cancers

View full text Add to dashboard Cite

Multiple Pulmonary Sclerosing Pneumocytomas (PSPs)

Wan,

Zhou,

Miao

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Pulmonary sclerosing pneumocytoma (PSP) is a rare neoplasm with indolent clinical behavior and usually presents as a solitary nodule, while only a few cases involving multiple nodules. Recent studies have revealed frequent AKT1 mutations in PSP; however, the molecular genetics of multiple PSPs remain unclear. To better understand the genetic background, eleven patients (4.2%, 11/260) with multiple PSP nodules were identified, and whole-exome sequencing (WES) was performed on 6 patients. Among 5 patients with 2 or 3 PSP nodules, AKT1 alterations were the most common (50%, 7/14), and the predominant alteration was p.E17K (21.4%, 3/14). Novel ARID1A mutations were the second most common driver (14.3%, 2/14), and we first identified these mutations cooccurred with AKT1 p.E17K mutation. Moreover, we observed limited concordance in the mutation spectra and few comutated genes among different lesions from these 5 patients, indicating that PSP with 2 or 3 nodules were independent arising tumors. No AKT1 mutations were identified in 3 PSP samples from a patient with multiple diffuse nodules. However, there were 17 shared genetic alterations among the 3 lesions, but none were typical driver mutations. The findings on multiple diffuse PSP nodules may also have independent origins, but the potential that some of these nodules are metastatic nodules cannot be excluded. In conclusion, this retrospective study is the largest series of multiple PSP cases and provides new insights into the genomic underpinning of PSP. This work has a potential to broaden our understanding of the pathogenesis and development of these lesions and warrants analysis in larger cohorts.

show abstract

Pulmonary sclerosing pneumocytoma masquerading adenocarcinoma with co-existing BRAF V600E and PTEN mutation

Cited by 8 publications

References 14 publications

Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Pulmonary Sclerosing Pneumocytoma

Multiple Pulmonary Sclerosing Pneumocytomas (PSPs)

Contact Info

Product

Resources

About